These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 17430426)
1. Oral phosphodiesterase-5 inhibitors: effect of heme oxygenase inhibition on cGMP signalling in rat cavernous tissue. Abdel Aziz MT; Mostafa T; Atta H; Rashed L; Marzouk SA; Obaia EM; Sabry D; Hassouna AA; El-Shehaby AM; Abdel Aziz AT Andrologia; 2007 Apr; 39(2):66-70. PubMed ID: 17430426 [TBL] [Abstract][Full Text] [Related]
2. The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues. Aziz MT; Mostafa T; Atta H; Rashed L; Marzouk SA; Obaia EM; Sabry D; Hassouna AA; El-Shehaby AM; Aziz AT J Sex Med; 2008 Jul; 5(7):1636-45. PubMed ID: 18208506 [TBL] [Abstract][Full Text] [Related]
3. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum. Hallén K; Wiklund NP; Gustafsson LE Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379 [TBL] [Abstract][Full Text] [Related]
5. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958 [TBL] [Abstract][Full Text] [Related]
6. Assessment of heme oxygenase-1 (HO-1) activity in the cavernous tissues of sildenafil citrate-treated rats. Aziz MT; Al-Asmar MF; Mostafa T; Atta H; Rashed L; Sabry D; Ashour S; Aziz AT Asian J Androl; 2007 May; 9(3):377-81. PubMed ID: 17486279 [TBL] [Abstract][Full Text] [Related]
7. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. Teixeira CE; Priviero FB; Webb RC J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472 [TBL] [Abstract][Full Text] [Related]
8. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects. Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324 [TBL] [Abstract][Full Text] [Related]
9. Heme oxygenase vs. nitric oxide synthase in signaling mediating sildenafil citrate action. Abdel Aziz MT; El-Asmer MF; Mostafa T; Mostafa S; Atta H; Aziz Wassef MA; Fouad H; Rashed L; Sabry D; Mahfouz S J Sex Med; 2007 Jul; 4(4 Pt 2):1098-107. PubMed ID: 17627722 [TBL] [Abstract][Full Text] [Related]
10. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306 [TBL] [Abstract][Full Text] [Related]
11. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum. Lau LC; Adaikan PG Eur J Pharmacol; 2006 Jul; 541(3):184-90. PubMed ID: 16777087 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Bessay EP; Zoraghi R; Blount MA; Grimes KA; Beasley A; Francis SH; Corbin JD Front Biosci; 2007 Jan; 12():1899-910. PubMed ID: 17127429 [TBL] [Abstract][Full Text] [Related]
14. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515 [TBL] [Abstract][Full Text] [Related]
15. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Rosen RC; Kostis JB Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619 [TBL] [Abstract][Full Text] [Related]
16. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278 [TBL] [Abstract][Full Text] [Related]
17. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941 [TBL] [Abstract][Full Text] [Related]
18. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Zhang L; Zhang Z; Zhang RL; Cui Y; LaPointe MC; Silver B; Chopp M Brain Res; 2006 Nov; 1118(1):192-8. PubMed ID: 16959227 [TBL] [Abstract][Full Text] [Related]
19. Novel water-soluble curcumin derivative mediating erectile signaling. Abdel Aziz MT; El Asmer MF; Rezq A; Kumosani TA; Mostafa S; Mostafa T; Atta H; Abdel Aziz Wassef M; Fouad HH; Rashed L; Sabry D; Hassouna AA; Senbel A; Abdel Aziz A J Sex Med; 2010 Aug; 7(8):2714-22. PubMed ID: 21711478 [TBL] [Abstract][Full Text] [Related]
20. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]